(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Figure out How to Back Your Rooftop Substitution - 2Argentina joins NASA’s moon return with microsatellite testing GPS beyond Earth
- 3Pick Your #1 Kind Of Bread
- 4Court clears Beersheba assault suspect of link to Haymanut Kasau disappearance, extends detention
- 5CDC clarifies stance on vaccines and autism, stating no evidence supports the link
- Clovis Unified students spend spring break traveling through China
- Nigeria’s return to Windsor castle signals new era in UK economic partnership
- IDF strikes Tehran command centers, weapon production sites
- Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes
- Where is Santa right now? NORAD tracks his 2025 Christmas Eve flight.
- 6 Famous kind of practice on the planet
- Allow Innovative Progressions To have a Massive Effect
- Newly Built Sichuan Hydropower Bridge Collapses Into River Months After Opening
- Exploring ways to reduce the impact of space junk on Earth
